Product information

PDS0201 is a novel investigational tuberculosis vaccine that generates broad and robust antibody and T cell responses that provide durable protection against bacillus Mycobacterium tuberculosis (M. tuberculosis). PDS0202 is given as a single dose by intramuscular injection and is being developed to provide robust and durable protection against tuberculosis.

Disease state

Tuberculosis (TB) is the leading cause of death from a single infectious agent and is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. It has been reported that a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).

Development status

PDS0201 is currently in pre-clinical development.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up


This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.